Ghana FDA drug registration: the local agent is the gate, and everything else waits behind it.

Most exporters approach Ghana as if it were a smaller Nigeria. It is not. The Food and Drugs Authority operates under the Public Health Act, 2012 (Act 851), whose Part 7 governs food and drugs, and the registration mechanics turn on one structural fact that is easy to read past: a foreign applicant must act through a local agent who is resident in Ghana. Everything else in the file, the dossier format, the GMP position, the labelling, sits behind that appointment. This is what the desk at M Care Exports has learned about how the Ghanaian file actually moves.

The legal basis, and why it matters to a buyer.

Drug regulation in Ghana sits under the Public Health Act, 2012 (Act 851). Part 7 of that Act covers food and drugs, and Sections 117 to 119 are the ones a regulatory affairs officer will actually cite: the application for registration, the registration itself, and the conditions attached to it. The Food and Drugs Authority is the body that administers this.

This matters commercially, not just legally. An importer in Accra buying from an Indian supplier is buying against a registration that exists under Act 851 and is held in Ghana. If the supplier changes, the registration does not automatically travel. If the local agent relationship breaks down, the buyer can find that the product they have been selling for three years is attached to a licence they do not control. That is the single most common structural problem we see raised by Ghanaian distributors, and it is a contracting problem rather than a regulatory one.

The local agent requirement, stated plainly.

A foreign manufacturer cannot file directly. The applicant must appoint a local agent resident in Ghana, and that agent carries the application. In practice the agent is the importer, a distributor, or a regulatory consultancy retained for the purpose.

Three consequences follow, and they are worth thinking through before the appointment letter is signed.

• The agent is the regulator's counterparty. Queries, deficiency letters and renewal notices go to the agent, not to the manufacturer in India. If the agent is slow, the file is slow, and the manufacturer often does not find out until a deadline has passed.
• The agent's identity is on the licence. Changing agent later is an administrative act with its own paperwork and its own delay. Treat the appointment as a multi-year decision rather than a convenience.
• Exclusivity is a commercial term, not a regulatory one. Act 851 does not require the agent to be your exclusive distributor. Whether they are is something you negotiate. Exporters routinely conflate the two and hand exclusivity away for free because they assume the regulator demanded it.

For a buyer, the reverse question is the useful one. If you are an importer being offered a product from India, ask who currently holds the Ghanaian registration and on whose agency it sits. If the answer is a competitor, you are quoting on a product you cannot legally import without going through them.

GMP and GCP compliance, and what the file has to show.

Compliance with Good Manufacturing Practice and Good Clinical Practice is mandatory in the Ghanaian framework. For a generic finished product coming out of India, the practical reading is that the manufacturing site must be able to evidence its GMP status, and any clinical or bioequivalence data in the dossier must have been generated to GCP.

M Care Exports is a merchant-exporter. We do not hold GMP ourselves and we are careful to say so. What we do is source from WHO-GMP certified Indian manufacturers and assemble the evidence pack that sits behind the claim: the site's GMP certificate, the certificate of pharmaceutical product, the batch documentation, and the stability data in the format the reviewer expects to see it.

Where files stall is rarely the existence of GMP. It is the mismatch between the GMP certificate and the rest of the file: a certificate naming a manufacturing block that does not match the block named on the CoPP, a scope that does not cover the dosage form being registered, or an expiry that lapses mid-review. Those are avoidable with a document check before submission, and they are the reason we run one.

The dossier and the cover letter that has to attest it.

Ghana works on a CTD-based dossier. If you have already built a Common Technical Document for another market, the bulk of Modules 2 and 3 will carry across, which is why exporters with an existing UK, Gulf or East African file find Ghana less painful than a first-time applicant does.

One requirement catches people out because it looks trivial. The application must be accompanied by a written cover letter attesting that the information submitted is true and accurate. It is a signed statement of truth, not a compliments slip. Treat it as the document a regulator will point to if something in the file turns out to be wrong, because that is what it is for.

Practical file discipline that saves a review cycle:

1. Confirm the CoPP and the GMP certificate name the same legal manufacturer and the same site.
2. Confirm the dosage form and strength on the certificates match the product being applied for, exactly, including salt form.
3. Check certificate validity against your realistic submission date, not today's date.
4. Have the artwork reflect Ghanaian labelling expectations before submission rather than after a deficiency letter.
5. Keep the agent's appointment letter current and on file with the application.

What we are not going to tell you.

We are not going to quote you a registration timeline for Ghana. Consultancies publish blended African figures, and one of the larger Indian exporters currently advertises a single 6 to 18 month range covering Nigeria, Kenya, Ghana, Tanzania and Ethiopia together, with no country breakdown. That number is not a Ghana timeline. It is an average across five very different regulators, and quoting it back to a buyer as though it were a commitment is how supply relationships start badly.

What is reasonable to say is that the variables are knowable: whether the dossier is already CTD-complete, whether the site certificates are current, whether the agent responds to queries within days or weeks, and whether the product is a straightforward generic or something requiring more assessment. Those are the levers. Anyone quoting a fixed number without asking about them is guessing.

Where a merchant-exporter fits in this.

We sit on the supply side of the agent relationship, not inside it. Our part is to make the Ghanaian file straightforward to assemble: to select manufacturing partners whose certificates will survive scrutiny, to supply the CoPP, GMP certificate, batch and stability documentation in the form the reviewer expects, and to keep supplying against the registration once it exists so the agent is not renewing a licence for a product they can no longer get.

We are not the applicant, we do not act as your Ghanaian agent, and we do not perform the registration. Those sit with you or your local partner. Being clear about that boundary is usually more useful to a buyer than a promise to handle everything.

Frequently asked

Can an Indian manufacturer register a medicine in Ghana without a local agent?

No. A foreign applicant must appoint a local agent resident in Ghana, and that agent files and holds the application. There is no direct-filing route for a foreign manufacturer, so the agent appointment is the first commercial decision, not an administrative afterthought.

Does the local agent have to be my exclusive distributor in Ghana?

Not as a matter of regulation. Act 851 requires a resident local agent; it does not dictate the commercial terms between you and that agent. Exclusivity is negotiated separately, and exporters frequently give it away because they assume the regulator required it.

Which law governs drug registration in Ghana?

The Public Health Act, 2012 (Act 851). Part 7 covers food and drugs, with Sections 117 to 119 dealing with the application for registration, the registration itself and the conditions attached to it. The Food and Drugs Authority administers the framework.

Will a CTD dossier prepared for another market work for Ghana?

Largely, yes. Ghana works on a CTD-based dossier, so an existing Common Technical Document gives you most of Modules 2 and 3. What changes is the country-specific administrative content, the local agent documentation, the labelling and artwork, and the certificates that must be current at the point of submission.

How long does Ghana FDA registration take?

We do not publish a figure, because an honest one depends on the file. Whether the dossier is already CTD-complete, whether the site certificates are current and correctly scoped, how quickly the local agent answers queries and how complex the product is all move the timeline materially. Blended African averages quoted by consultancies cover several regulators at once and should not be read as a Ghana commitment.

What does M Care Exports actually do on a Ghanaian registration?

We supply the product and the manufacturer-side evidence pack: the certificate of pharmaceutical product, the site GMP certificate, batch documentation and stability data, sourced from WHO-GMP certified Indian manufacturers. We are a merchant-exporter, not the applicant and not your Ghanaian agent, and we do not perform the registration itself.